Sitamet-Avenir 50/1000 mg

/ BioAvenir Ltd.

The dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the excipients’ maximum recommended daily doses.
In some cases, it may be necessary to stop taking this medicine for a short period:
• Dehydration.
• The patient is about to undergo surgery.
• The patient is about to receive an injection of a dye or contrast medium for an X-ray.

This medicinal product is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.
Important limitations of use:
This medicinal product should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
This medicinal product has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using this medicine.

Hypersensitivity to the active substances or to any of the excipients.
Type 1 diabetes.
Severely reduced renal function (eGFR below 30 mL/min/1.73 m²).
Diabetic ketoacidosis.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.